Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery

Blood

Volumn 89, Issue 2, 1997, Pages 411-418

  Sowade, Olaf ^b   Warnke, Harry ^b   Scigalla, Paul ^b   Sowade, Birgit ^a   Franke, Werner ^b   Messinger, Diethelm ^b   Gross, Johann ^b  

^a Hospital Berlin Kaulsdorf   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS ION; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODILUTION; HEMOGLOBIN DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OPEN HEART SURGERY; ORAL DRUG ADMINISTRATION; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT CONTRAINDICATION;

EID: 0031036078     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.2.411     Document Type: Article

References (33)

1. Goodnough LT, Johnston MFM, Toy PTC, Transfusion Medicine Academic Award Group: The variability of transfusion practice in coronary artery bypass surgery. JAMA 266:86, 1991
2. Welch HG, Meehan KR, Goodnough LT: Prudent strategies for elective red blood cell transfusion. Ann Intern Med 116:393, 1992
3. Cosgrove DM, Loop FD, Lytle BW, Fill CC, Golding LR, Taylor PC, Forsythe SB: Determinants of blood utilization during myocardial revascularization. Ann Thorac Surg 40:380, 1985
4. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T: Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 55:971, 1993
5. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73, 1987
6. Biesma DH, Marx JJM, Kraaijenhagen RJ, Franke W, Messinger D, van de Wiel A: Lower homologous blood requirement in autologous donors after treatment with recombinant human erythropoietin. Lancet 344:367, 1994
7. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, Silberstein LE, Smith KJ, Wallas CH, Abels R, von Tress M: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321:1163, 1989
8. Schmoeckel M, Nollert G, Mempel M, Mempel W, Reichart B: Effects of recombinant human erythropoietin on autologous blood donation before open-heart surgery. Thorac Cardiovasc Surg 41:364, 1993
9. Scott WJ, Rode R, Castlemain B, Kessler R, Follis F, Pett SB, Wernly JA: Efficacy, complications and costs of a comprehensive blood conservation programm for cardiac operations. J Thorac Cardiovasc Surg 103:1001, 1992
10. Sowade O, Warnke H, Sowade B, Gross J, Bohm J, Messinger D, Scigalla P: Avoidance of homologous blood transfusion and increase of oxygen availability by preoperative epoetin beta therapy in patients undergoing coronary artery bypass grafting (CABG). Blood 86:352a, 1995 (suppl 1, abstr)
11. Sowade O, Warnke H, Scigalla P: Results of open-heart surgery in adult members of Jehovah's Witnesses. Anaesthesist 44:257, 1995
12. Robertie PG, Gravlee GP: Safe limits of isovolemic hemodilution and recommendations for erythrocyte transfusion. Int Anaesthesiol Clin 28:197, 1990
13. Goodnough LT, Despotis GJ, Hogue CH, Ferguson TB: On the need for improved transfusion indicators in cardiac surgery. Ann Thorac Surg 60:473, 1995
14. Casagrande JT, Pike MC, Smith PG: An improved approximate formula for calculating sample sizes for comparing two binominal distributions. Biometrics 34:483, 1978
15. Nadler S, Hidalzo J, Bloch T: Prediction of blood volume in normal human adults. Surgery 51:224, 1962
16. Hammermeister KE, Burchfiel C, Johnson R, Grover FL: Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation 82:IV-380, 1990 (suppl 4)
17. Geraci JM, Rosen AK, Ash AS, McNiff J, Moskowitz MA: Predicting the occurrence of adverse events after coronary artery bypass surgery. Ann Intern Med 118:18, 1993
18. Knight AA, Hollenberg M, London MJ, Tubau J, Verrier E, Browner W, Mangano D: Perioperative myocardial ischemia, importance of the preoperative ischemic pattern. Anesthesiology 68:681, 1988
19. Duke M, Abelman WH: The hemodynamic response to chronic anemia. Circulation 39:503, 1969
20. Lewis CTP, Murphy MC, Cooley DA: Risk factors for cardiac operations in adult Jehovah's Witnesses. Ann Thorac Surg 51:448, 1991
21. Canadian Orthopedic Perioperative Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 341:1227, 1993
22. Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T: Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open-heart surgery. Circulation 86:II-413, 1992 (suppl 2)
23. Kyo S, Omoto R, Hirashima K, Eguchi S, Fujita T: Effect of human recombinant erythropoietin on reduction of homologous blood transfusion in open-heart surgery - A Japanese multicenter study. Circulation 86:II-17, 1992 (suppl 2, abstr 2851a)
24. Bommer J, Ritz E, Weinreich T, Bommer G, Ziegler T: Subcutaneous erythropoietin. Lancet 2:406, 1988 (letter)
25. McMahon FG, Vargas R, Ryan M, Jain Ak, Abels RI, Perry B, Smith IL: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. Blood 76:1718, 1990
26. Rutherford CJ, Schneider TJ, Dempsey H, Kirn DH, Brugnara C, Goldberg MA: Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting - The importance of iron availability in optimizing response. Am J Med 96:139, 1994
27. Levine EA, Gould SA, Rosen AL, Sehgal LR, Egrie JC, Sehgal HL, Levine HD, Moss GS: Perioperative recombinant human erythropoietin. Surgery 106:432, 1989
28. Schooley JC, Kullgren B, Allison AC: Inhibition by interleukin 1 of the action of erythropoietin on erythroid processors and its possible role in the pathogenesis of hypoplastic anaemia. Br J Haematol 67:11, 1987
29. McDougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 299:157, 1989
30. Brugnara C, Colella GM, Cremins J, Langley RC, Schneider TJ, Rutherford CJ, Goldberg MA: Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 123:660, 1994
31. Skikne BS, Cook JD: Effect on enhanced erythropoiesis on iron absorption. J Lab Clin Med 120:746, 1992
32. Price TH, Goodnough LT, Vogler WR, Sacher RA, Hellman RM, Johnston MFM: The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: A multicenter, randomized, double-blind, controlled trial. Transfusion 36:29, 1996
33. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York, NY, Wiley, 1973